Aceclidine

Aceclidine is an agent that is used for treating glaucoma by reducing intraocular pressure. Aceclidine is a modulator of M3 muscarinic acetylcholine receptor, making it relevant to research on disorders such as refractive errors of the eye, xerostomia, Sjogren's syndrome, glaucoma, conjunctivitis, lacrimal gland disease, and esotropia. Aceclidine exhibits 28-fold iris-over-ciliary muscle selectivity and a 270% outflow facility increase with only 5D accommodation (vs. 19D with pilocarpine), making it the optimal reference for presbyopia R&D and IOP-lowering agent development. Aceclidine is also classified as a cycloplegic agent, a surfactant, a tonicity adjustor, and optionally a viscosity enhancer and an antioxidant.

 

Product Parameters

---

Parameter	Specification
Product Name	Aceclidine
CAS Number	827-61-2
Molecular Formula	C₉H₁₅NO₂
Molecular Weight	169.22 g/mol
Appearance	Off-white to light yellow; solid below 34 °C, liquid above 36 °C
Boiling Point	298.52 °C (rough estimate)
Density	1.0873 g/cm³ (rough estimate)
Refractive Index	1.4780 (estimate)
pKa	9.22 ± 0.33 (Predicted)
Storage Condition	Sealed in dry; store in freezer under −20 °C

Synthetic Route

---

→

 The synthesis of the (RS)-3-acetoxyquinine ring was carried out by dissolving (RS)-3-quinine ring alcohol (25 g, 0.2 mol) in pyridine (100 ml) and slowly adding acetic anhydride (100 ml). The reaction mixture was stirred at 50 °C for 4 hours, followed by incubation at room temperature for 15 hours. Upon completion, pyridine and excess acetic anhydride were removed by vacuum distillation. The resulting light brown oily product was dissolved in water (25 ml) and adjusted to a weak alkaline solution with saturated potassium carbonate. The mixture was then extracted with chloroform (5 × 50 ml); the organic phases were combined and dried with anhydrous potassium carbonate. The organic phase was concentrated under reduced pressure, and the residue was purified by distillation to yield 20.6 g of (RS)-3-acetoxyquinine ring (yield: 62%).

Application

---

The combination of Aceclidine with low-concentration selective α-2 adrenergic receptor agonists (α-2 agonists or α-2 adrenergic agonists), such as fadolmidine, bromomonidine, or guanafexine, can achieve the desired mydriatic effect and is indicated for the treatment of hyperopia.

 

Why Cosperpharm?

---

When your ophthalmic research or pharmaceutical development requires Aceclidine for glaucoma or muscarinic receptor studies, Cosperpharm delivers with the quality and reliability that researchers expect.

 

Proven pharmacological profile. Aceclidine exhibits 28-fold iris-over-ciliary muscle selectivity and a 270% outflow facility increase, making it the optimal reference for presbyopia R&D and IOP-lowering agent development. Our rigorous quality control ensures batch-to-batch consistency.

 

Documentation for your research. Every shipment of Aceclidine includes a Certificate of Analysis (COA) with batch-specific purity and identity data.

 

Flexible supply for all needs. Cosperpharm supplies Aceclidine from research quantities for in vitro studies to larger quantities for formulation development.

 

Technical support when you need it. Our team can advise on solubility, stability, and application-specific considerations.

 

Contact Us

---

Looking for Aceclidine for your ophthalmic research or muscarinic receptor studies? Cosperpharm is here to help — reach out today.